Mirabilis Medica, Inc. is in clinical development of a non-invasive therapeutic ultrasound platform with an initial application to the treatment of uterine fibroids. Symptomatic uterine fibroids affect approximately 25% of all women at some point in their lives,(1) and can cause pain, abnormal bleeding, pregnancy loss and infertility.(2)
The Mirabilis platform uses high resolution ultrasound imaging to localize treatment, and a proprietary ultrasound technology to quickly and non-invasively treat tissue deep in the body. The company believes that this treatment modality has several other potential clinical applications.
The Mirabilis platform has not been approved for sale or use by the US Food and Drug Administration.
References:
1. Laughlin KL, Stewart EA. Uterine Leiomyomas. Obstet Gynecol 2011;117:396-403
2. Brahma PK, Martel KM. Future Directions in Myoma Research. Obstet Gynecol clin 2006;33:199-244
Copyright (c) 2012 Mirabilis Medica, Inc. - All Rights Reserved